German (DAX) Pharma Industry Analysis

Industry Valuation and Performance

Has the German Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 21 Jun 2026	€98.0b	€67.4b	€482.5m	22.8x	203.2x	1.5x
Tue, 19 May 2026	€91.5b	€67.4b	€511.2m	18.6x	179x	1.4x
Thu, 16 Apr 2026	€94.3b	€67.9b	-€883,903,815.65	19x	-106.7x	1.4x
Sat, 14 Mar 2026	€88.0b	€67.9b	-€900,283,686.17	18.5x	-97.7x	1.3x
Mon, 09 Feb 2026	€100.6b	€68.3b	€2.9b	17.4x	35.1x	1.5x
Wed, 07 Jan 2026	€95.3b	€68.3b	€2.9b	18.3x	33.3x	1.4x
Fri, 05 Dec 2025	€88.0b	€68.5b	€2.9b	17.6x	30.5x	1.3x
Sun, 02 Nov 2025	€78.9b	€68.8b	-€439,034,439.69	19.5x	-179.7x	1.1x
Tue, 30 Sep 2025	€76.9b	€68.8b	-€438,978,145.85	18.7x	-175.1x	1.1x
Thu, 28 Aug 2025	€78.1b	€68.9b	-€406,124,709.46	17.6x	-192.3x	1.1x
Sat, 26 Jul 2025	€80.1b	€69.4b	-€283,071,598.00	17.8x	-283.1x	1.2x
Mon, 23 Jun 2025	€76.6b	€69.4b	-€293,702,195.00	17.3x	-260.8x	1.1x
Wed, 21 May 2025	€76.5b	€69.4b	-€196,350,479.00	17.4x	-389.6x	1.1x
Fri, 18 Apr 2025	€73.9b	€69.3b	€463.1m	17.8x	159.6x	1.1x
Sun, 16 Mar 2025	€84.0b	€69.2b	€436.0m	21.1x	192.7x	1.2x
Tue, 11 Feb 2025	€82.1b	€69.2b	€2.0b	21.8x	40.5x	1.2x
Thu, 09 Jan 2025	€84.3b	€69.2b	€2.0b	23.1x	41.9x	1.2x
Sat, 07 Dec 2024	€83.0b	€69.2b	€2.0b	22.5x	41x	1.2x
Mon, 04 Nov 2024	€93.9b	€69.4b	€1.6b	20.1x	60.2x	1.4x
Wed, 02 Oct 2024	€100.3b	€69.3b	€1.5b	22.8x	68.2x	1.4x
Fri, 30 Aug 2024	€105.8b	€69.4b	€1.5b	25.8x	71.8x	1.5x
Sun, 28 Jul 2024	€98.8b	€69.2b	-€303,627,757.00	29.5x	-325.3x	1.4x
Tue, 25 Jun 2024	€101.4b	€69.2b	-€327,989,929.00	30.8x	-309.2x	1.5x
Thu, 23 May 2024	€103.8b	€69.2b	-€310,351,180.00	21.8x	-334.3x	1.5x
Sat, 20 Apr 2024	€91.9b	€70.0b	-€34,208,180.00	20.1x	-2685.9x	1.3x
Mon, 18 Mar 2024	€96.5b	€70.0b	€6.5m	19.8x	14855.7x	1.4x
Wed, 14 Feb 2024	€95.9b	€70.6b	-€650,504,143.00	19.8x	-147.4x	1.4x
Fri, 12 Jan 2024	€97.6b	€70.6b	-€650,504,143.00	20.2x	-150.1x	1.4x
Sun, 10 Dec 2023	€95.8b	€70.6b	-€650,606,256.00	18.2x	-147.2x	1.4x
Tue, 07 Nov 2023	€107.6b	€72.1b	€4.7b	17.6x	23x	1.5x
Thu, 05 Oct 2023	€113.9b	€72.1b	€4.7b	19.3x	24.4x	1.6x
Sat, 02 Sep 2023	€125.5b	€72.1b	€4.7b	22.2x	27x	1.7x
Mon, 31 Jul 2023	€124.2b	€74.1b	€6.5b	17.3x	19.3x	1.7x
Wed, 28 Jun 2023	€118.6b	€74.2b	€6.4b	18x	18.4x	1.6x

Current Industry PE

Investors are optimistic on the German Pharmaceuticals industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 203x which is higher than its 3-year average PE of 131x.

The industry is trading close to its 3-year average PS ratio of 1.3x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have declined 58% per year over the last three years,
Revenues have also declined 3.1% per year.
This means overall sales from these companies are declining and profits are subsequently falling as well.

Industry Trends

Which industries have driven the changes within the German Healthcare industry?


DE Market	0.64%
Healthcare	0.42%
Pharma	1.41%
Pharma	1.41%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

	Company	Last Price	7D	1Y	Valuation
	BAYN Bayer	€37.84	4.6% +€1.6b	41.8%	PS0.8x
	93M1 MPH Health Care	€28.10	1.8% +€2.1m	44.1%	PS2.4x

Company

Last Price

Valuation

BAYN Bayer

€37.84

4.6%
+€1.6b

41.8%

PS0.8x

93M1 MPH Health Care

€28.10

1.8%
+€2.1m

44.1%

PS2.4x

Merck Announces Management Appointments

Merck announced the appointments of Clara Sattler de Sousa e Brito as Head of Discovery Solutions and Robert Machinek as Head of Strategy & Business Development for the company’s Life Science business. Sattler de Sousa e Brito will assume her role in the third quarter of 2026 and Machinek assumes his role effective June 8, 2026. As Head of Discovery Solutions, Sattler de Sousa e Brito will lead the business unit focused on supporting research and early-stage discovery with digital tools, trusted products and innovative technologies across biology, chemistry and analytical workflows. Sattler de Sousa e Brito joins Merck from Philips International BV, where she served as EVP and Market Leader Europe. Previously, she held international senior roles at Siemens Healthineers and The Linde Group, with P&L responsibility across healthcare, medical technology and chemical industries. She brings extensive experience in commercial execution, business development and digital transformation, with a focus on driving growth and innovation through customer-centric leadership and high-performing teams. Machinek assumes his role effective immediately. As Head of Strategy & Business Development, Machinek will lead the organization responsible for shaping and executing the Life Science strategy, guiding organic and inorganic growth, ensuring strategic alignment across business units and regions, and overseeing the ERP business program. In this role, he will help advance the company’s strategic priorities and support the continued evolution of the Life Science business. Machinek served as interim head of the organization prior to his appointment to the role. Before joining Merck, Machinek was a Partner at McKinsey & Company, where he led strategic life science and healthcare engagements across North America, Europe and Asia. His expertise spans strategic growth, major ERP transformations, M&A, digital initiatives and global operations optimization. Machinek holds a PhD in Physics from the University of Oxford and a B.Sc. in Physics from RWTH Aachen University.

German (DAX) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Bayer Appoints Kacy Perry as Country Division Head for Crop Science Canada, Effective July 1, 2026

Merck Announces Management Appointments

MPH Health Care AG, Annual General Meeting, Jul 09, 2026

New major risk - Revenue and earnings growth

Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026

Cantourage Group SE, Annual General Meeting, Jun 24, 2026

SynBiotic SE, Annual General Meeting, Apr 23, 2026

Cannovum Cannabis AG, Annual General Meeting, Nov 20, 2025